Attention Deficit Disorders With Hyperactivity
7
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
1 terminated out of 7 trials
80.0%
-6.5% vs benchmark
29%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Pharmacogenomics for Improving Pediatric ADHD Treatment
Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)